The content on this site is intended for healthcare professionals only
Dr Jayant Vaidya speaks to ecancer about new clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy (IORT) during lumpectomy for breast cancer.
He explains the trial compared risk adapted single dose IORT given during lumpectomy for breast cancer versus standard post-operative breast radiotherapy given over the course of roughly 3-6 weeks.
The primary outcome was non-inferiority in local recurrence at five years which was proven. For overall survival there was no difference between the two treatment arms. However, in the IORT arm, death from other causes were significantly reduced. In further analysis, this translated to an overall survival benefit and an improvement in quality of life for patients.
Dr Vaidya concludes by highlighting the potential impact of these results in the future treatment of breast cancer.
Read the study here.
Visit the TARGIT website here.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Breast and emerging indications for IORT
The advantages of IORT for early breast cancer treatment
The pros and cons of breast IORT and ultra hypofractionation (FR)
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Global adoption of single-shot targeted IORT for breast cancer
IORT at the Asian Hospital and Medical Center
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Surgical management of Axilla: Past, present and future
